Comparison of viral glycosylation using lectin blotting with Vero cell-derived and mouse brain-derived Japanese encephalitis vaccines

Vaccine

Volumn 29, Issue 10, 2011, Pages 1859-1862

  Toriniwa, Hiroko ^a   Komiya, Tomoyoshi ^a  

^a KITASATO INSTITUTE   (Japan)

Author keywords

Glycosylation; Japanese encephalitis vaccine; Lectin

Indexed keywords

JAPANESE ENCEPHALITIS VACCINE; LECTIN; VIRUS PROTEIN;

ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; GLYCOSYLATION; IMMUNOBLOTTING; IMMUNOGENICITY; IMMUNOREACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VERO CELL; VIRAL GLYCOSYLATION; WESTERN BLOTTING;

ANIMALS; BRAIN; CERCOPITHECUS AETHIOPS; CULTURE MEDIA, SERUM-FREE; GLYCOPROTEINS; GLYCOSYLATION; JAPANESE ENCEPHALITIS VACCINES; LECTINS; MICE; VACCINES, INACTIVATED; VERO CELLS; VIRAL PROTEINS;

EID: 79951721238     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.12.038     Document Type: Article

References (22)

1. Burke D.S., Monath T.P. Fields virology 2001, Lippincott, Philadelphia, pp. 991-1055. 4th ed.
2. Tsai T.F. New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13-15 October 1998. Vaccine 2000, 18(Suppl. 2):1-25.
3. Chambers T.J., Hahn C.S., Galler R., Rice C.M. Flavivirus genome organization, expression, and replication. Annu Rev Microbiol 1990, 44:649-688.
4. Srivastava A.K., Aira Y., Mori C., Kobayashi Y., Igarashi A. Antigenicity of Japanese encephalitis virus envelope glycoprotein V3 (E) and its cyanogen bromide cleaved fragments examined by monoclonal antibodies and Western blotting. Arch Virol 1987, 96(1-2):97-107.
5. Konishi E., Yamaoka M., Khin-Sane-Win, Kurane I., Takada K., Mason P.W. The anamnestic neutralizing antibody response is critical for protection of mice from challenge following vaccination with a plasmid encoding the Japanese encephalitis virus premembrane and envelope genes. J Virol 1999, 73(7):5527-5534.
6. Srivastava A.K., Putnak J.R., Lee S.H., Hong S.P., Moon S.B., Barvir D.A., et al. A purified inactivated Japanese encephalitis virus vaccine made in Vero cells. Vaccine 2001, 19(31):4557-4565.
7. Sugawara K., Nishiyama K., Ishikawa Y., Abe M., Sonoda K., Komatsu K., et al. Development of Vero cell-derived inactivated Japanese encephalitis vaccine. Biologicals 2002, 30(4):303-314.
8. World Health Organization Acceptability of cell substrates for production of biologicals. WHO Tech Rep Ser 1987, 747:1-29.
9. World Health Organization Requirements for continuous cell lines used for biological substances. WHO Tech Rep Ser 1987, 745:99-115.
10. Froud S.J. The development, benefits and disadvantages of serum-free media. Dev Biol Stand 1999, 99:157-166.
11. Toriniwa H., Komiya T. Long-term stability of Vero cell-derived inactivated Japanese encephalitis vaccine prepared using serum-free medium. Vaccine 2008, 26(29-30):3680-3689.
12. Ferguson M., Kurane I., Wimalaratne O., Shin J., Wood D. WHO informal consultation on the scientific basis of specifications for production and control of inactivated Japanese encephalitis vaccines for human use, Geneva, Switzerland, 1-2 June 2006. Vaccine 2007, 25(29):5233-5243. WHO Informal Consultation Group.
13. Toriniwa H., Komiya T. Japanese encephalitis virus production in Vero cells with serum-free medium using a novel oscillating bioreactor. Biologicals 2007, 35(4):221-226.
14. Minimum requirements for biological products. Japan: National Institute of Infectious Diseases; 2006.
15. Kimura-Kuroda J., Yasui K. Antigenic comparison of envelope protein E between Japanese encephalitis virus and some other flaviviruses using monoclonal antibodies. J Gen Virol 1986, 67(Pt. 12):2663-2672.
16. Kuzuhara S., Nakamura H., Hayashida K., Obata J., Abe M., Sonoda K., et al. Non-clinical and phase I clinical trials of a Vero cell-derived inactivated Japanese encephalitis vaccine. Vaccine 2003, 21(31):4519-4526.
17. Rawling J., Melero J.A. The use of monoclonal antibodies and lectins to identify changes in viral glycoproteins that are influenced by glycosylation: the case of human respiratory syncytial virus attachment (G) glycoprotein. Methods Mol Biol 2007, 379:109-125.
18. Hanna S.L., Pierson T.C., Sanchez M.D., Ahmed A.A., Murtadha M.M., Doms R.W. N-linked glycosylation of West Nile virus envelope proteins influences particle assembly and infectivity. J Virol 2005, 79(21):13262-13274.
19. Mondotte J.A., Lozach P.Y., Amara A., Gamarnik A.V. Essential role of dengue virus envelope protein N glycosylation at asparagine-67 during viral propagation. J Virol 2007, 81(13):7136-7148.
20. Trujillo J.D., Kumpula-McWhirter N.M., Hötzel K.J., Gonzalez M., Cheevers W.P. Glycosylation of immunodominant linear epitopes in the carboxy-terminal region of the caprine arthritis-encephalitis virus surface envelope enhances vaccine-induced type-specific and cross-reactive neutralizing antibody responses. J Virol 2004, 78(17):9190-9202.
21. Hobson-Peters J., Toye P., Sánchez M.D., Bossart K.N., Wang L.F., Clark D.C., et al. A glycosylated peptide in the West Nile virus envelope protein is immunogenic during equine infection. J Gen Virol 2008, 89(Pt. 12):3063-3072.
22. Raju T.S., Briggs J.B., Borge S.M., Jones A.J. Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. Glycobiology 2000, 10(5):477-486.